Schmallenberg virus (sbv) vaccine, methods of production, and uses thereof
AssigneeBoehringer Ingelheim Vetmedica GmbH
InventorsVeljko NIKOLIN, Konrad STADLER, Axel LISCHEWSKI, Alexander BRIX, Jeffrey P. KNITTEL, Katharina Hedwig TOEPFER
Life of this patent
Estimating the term…
Abstract
The present invention relates to the field of vaccines and medicaments for the prophylaxis and treatment of infectious diseases in ruminants. In particular, it relates to inactivated Schmallenberg virus (SBV) useful as vaccine or medicament for preventing or treating viremia, the transmission and clinical symptoms, in particular malformations in newborn ruminants such as cattle, sheep and goats, induced by SBV.
Claims53
An immunogenic composition comprising one or more antigens of the Schmallenberg virus (SBV).
A method for the production of SBV, comprising the steps of:
- (a) infecting cells with a SBV;
- (b) cultivating the infected cells;
- and
- (c) harvesting the SBV produced by said cells.
The method according to claim 30, further comprising the steps of:
- (m) infecting insect cells with the SBV harvested in step (l);
- (n) cultivating the infected cells of step (m);
- and
- (o) harvesting the SBV produced by said cells in step (n).
A SBV comprising:
- (a) a small (S) RNA segment having a sequence that is inverse complementary to a nucleic acid sequence having at least 97.8% sequence identity with the nucleic acid sequence of SEQ ID NO:1 or SEQ ID NO:7;
- (b) a medium (M) RNA segment having a sequence that is inverse complementary to a nucleic acid sequence having at least 82.2% sequence identity with the nucleic acid sequence of SEQ ID NO:2;
- (c) a large (L) RNA segment having a sequence that is inverse complementary to a nucleic acid sequence having at least 93% sequence identity with the nucleic acid sequence of SEQ ID NO:3;
- or
- (d) combinations thereof.
A SBV comprising:
- (a) an S RNA segment, characterized in that the S RNA segment has a sequence having at least 97.8% sequence identity to SEQ ID NO:4 or SEQ ID NO:8;
- (b) an M RNA segment, characterized in that the M RNA segment has a sequence having at least 82.2% sequence identity to SEQ ID NO:5;
- (c) an L RNA segment, characterized in that the L RNA segment has a sequence having at least 93% sequence identity to SEQ ID NO:6;
- or
- (d) combinations thereof.
Dependencies are inferred from the claim text.